Comparison of ⁶⁸Ga-FAPI-04 and ¹⁸F-FDG PET/CT for diagnosis of metastatic lesions in patients with recurrent papillary thyroid carcinoma.

IF 0.9 4区医学 Q4 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

Hellenic journal of nuclear medicine Pub Date : 2023-01-01 DOI:10.1967/s002449912560

Zeynel Abidin Sayiner, Umut Elboğa, Ertan Sahin, Sadettin Ozturk, Yusuf Burak Cayirli, Yusuf Zeki Celen, Ersin Akarsu, Ilkay Dogan, Benan Kilbas, Kurtulus Eryilmaz, Davut Cakici

{"title":"Comparison of 68Ga-FAPI-04 and 18F-FDG PET/CT for diagnosis of metastatic lesions in patients with recurrent papillary thyroid carcinoma.","authors":"Zeynel Abidin Sayiner, Umut Elboğa, Ertan Sahin, Sadettin Ozturk, Yusuf Burak Cayirli, Yusuf Zeki Celen, Ersin Akarsu, Ilkay Dogan, Benan Kilbas, Kurtulus Eryilmaz, Davut Cakici","doi":"10.1967/s002449912560","DOIUrl":null,"url":null,"abstract":"Objective: We aimed to evaluate the gallium-68-labeled fibroblast-activation protein inhibitor (68Ga-FAPI) positron emission tomography/computed tomography (PET/CT) in localizing papillary thyroid carcinoma (PTC) foci in patients with biochemical relapse. Papillary thyroid carcinoma has achieved biochemical recovery after appropriate treatment and had biochemical relapse in the last follow-up were included in this retrospective study. Gallium-68-FAPI and fluorine-18-fluorodeoxyglucose (68F-FDG) PET/CT were performed to detect recurrence foci.Subjects and methods: Biochemically relapsed patients who underwent total thyroidectomy and were diagnosed with pathologically differentiated thyroid cancer were included in our study. Gallium-68-FAPI and 18F-FDG PET/CT imaging methods were used to determine the focus of metastasis or recurrence in all patients.Results: Among 29 patients enrolled to the study, pathological subgroups were papillary (n=26) and poorly differentiated (n=3) PTC. Anti-thyroglobulin (TG) antibody positivity were noted in 5 of the patients, while all 29 of them were TG positive and had been consist of three groups as follows: 2-10ng/mL (n=4), 11-300ng/mL (n=14), 301ng/mL and above (n=11). Recurrence was detected in 72.4% (n=21) and 86% (n=25) of the patients via 18F-FDG and 68Ga-FAPI, respectively. Accuracy of detection noted as 100% (5/5), 75% (3/4), and 92.9% (13/14) in groups with the anti-TG antibody positivity, TG levels of 2-10ng/mL and 11-300ng/mL, respectively, when the two imaging modalities were utilized together. Furthermore, accuracy of 68Ga-FAPI was 100% (11/11) in the group with TG levels of 301ng/mL and above, whereas accuracy of 18F-FDG was 81.8% (9/11). Lastly, median maximum standardized uptake value (SUVmax) of recurrent lesions detected by the 68Ga-FAPI (median SUVmax: 6.0) were statistically higher than the ones detected by the 18F-FDG (median SUVmax: 3.7) (P=0.002).Conclusion: In recurrent PTC especially in case of higher TG levels, 68Ga-FAPI can be used in patients with inconclusive 18F-FDG findings.","PeriodicalId":12871,"journal":{"name":"Hellenic journal of nuclear medicine","volume":"26 1","pages":"41-46"},"PeriodicalIF":0.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hellenic journal of nuclear medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1967/s002449912560","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: We aimed to evaluate the gallium-68-labeled fibroblast-activation protein inhibitor (⁶⁸Ga-FAPI) positron emission tomography/computed tomography (PET/CT) in localizing papillary thyroid carcinoma (PTC) foci in patients with biochemical relapse. Papillary thyroid carcinoma has achieved biochemical recovery after appropriate treatment and had biochemical relapse in the last follow-up were included in this retrospective study. Gallium-68-FAPI and fluorine-18-fluorodeoxyglucose (⁶⁸F-FDG) PET/CT were performed to detect recurrence foci.

Subjects and methods: Biochemically relapsed patients who underwent total thyroidectomy and were diagnosed with pathologically differentiated thyroid cancer were included in our study. Gallium-68-FAPI and ¹⁸F-FDG PET/CT imaging methods were used to determine the focus of metastasis or recurrence in all patients.

Results: Among 29 patients enrolled to the study, pathological subgroups were papillary (n=26) and poorly differentiated (n=3) PTC. Anti-thyroglobulin (TG) antibody positivity were noted in 5 of the patients, while all 29 of them were TG positive and had been consist of three groups as follows: 2-10ng/mL (n=4), 11-300ng/mL (n=14), 301ng/mL and above (n=11). Recurrence was detected in 72.4% (n=21) and 86% (n=25) of the patients via ¹⁸F-FDG and ⁶⁸Ga-FAPI, respectively. Accuracy of detection noted as 100% (5/5), 75% (3/4), and 92.9% (13/14) in groups with the anti-TG antibody positivity, TG levels of 2-10ng/mL and 11-300ng/mL, respectively, when the two imaging modalities were utilized together. Furthermore, accuracy of ⁶⁸Ga-FAPI was 100% (11/11) in the group with TG levels of 301ng/mL and above, whereas accuracy of ¹⁸F-FDG was 81.8% (9/11). Lastly, median maximum standardized uptake value (SUVmax) of recurrent lesions detected by the ⁶⁸Ga-FAPI (median SUVmax: 6.0) were statistically higher than the ones detected by the ¹⁸F-FDG (median SUVmax: 3.7) (P=0.002).

Conclusion: In recurrent PTC especially in case of higher TG levels, ⁶⁸Ga-FAPI can be used in patients with inconclusive ¹⁸F-FDG findings.

查看原文本刊更多论文

68Ga-FAPI-04与18F-FDG PET/CT对复发性甲状腺乳头状癌转移灶诊断的比较

目的:探讨镓-68标记成纤维细胞活化蛋白抑制剂(68Ga-FAPI)正电子发射断层扫描/计算机断层扫描(PET/CT)在生化复发患者甲状腺乳头状癌(PTC)病灶定位中的应用价值。本回顾性研究纳入甲状腺乳头状癌经适当治疗后生化恢复，最后一次随访生化复发的患者。采用镓-68- fapi和氟-18-氟脱氧葡萄糖(68F-FDG) PET/CT检测复发灶。研究对象和方法:我们的研究对象是接受甲状腺全切除术并诊断为病理分化甲状腺癌的生化复发患者。采用镓-68- fapi和18F-FDG PET/CT成像方法确定所有患者转移或复发的病灶。结果:纳入研究的29例患者中，病理亚组为乳头状PTC (n=26)和低分化PTC (n=3)。5例患者抗甲状腺球蛋白(TG)抗体阳性，29例均为TG阳性，分为2 ~ 10ng/mL (n=4)、11 ~ 300ng/mL (n=14)、301ng/mL及以上(n=11)三组。通过18F-FDG和68Ga-FAPI分别检测到72.4% (n=21)和86% (n=25)的患者复发。在抗TG抗体阳性、TG水平为2-10ng/mL和11-300ng/mL的组中，两种成像方式同时使用时，检测准确率分别为100%(5/5)、75%(3/4)和92.9%(13/14)。此外，在TG水平为301ng/mL及以上的组中，68Ga-FAPI的准确性为100%(11/11)，而18F-FDG的准确性为81.8%(9/11)。最后，68Ga-FAPI检测到的复发病灶的最大标准化摄取值中位数(SUVmax中位数:6.0)高于18F-FDG检测到的最大标准化摄取值中位数(SUVmax中位数:3.7)(P=0.002)。结论:对于复发性PTC，特别是TG水平较高的患者，68Ga-FAPI可用于18F-FDG不确定的患者。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hellenic journal of nuclear medicine 医学-核医学

CiteScore

1.40

自引率

6.70%

发文量

审稿时长

>12 weeks

期刊介绍： The Hellenic Journal of Nuclear Medicine published by the Hellenic Society of Nuclear Medicine in Thessaloniki, aims to contribute to research, to education and cover the scientific and professional interests of physicians, in the field of nuclear medicine and in medicine in general. The journal may publish papers of nuclear medicine and also papers that refer to related subjects as dosimetry, computer science, targeting of gene expression, radioimmunoassay, radiation protection, biology, cell trafficking, related historical brief reviews and other related subjects. Original papers are preferred. The journal may after special agreement publish supplements covering important subjects, dully reviewed and subscripted separately.